DelveInsight’s, “Systemic Mastocytosis Pipeline Insight, 2025,” report provides comprehensive insights about 8+ companies and ...

Tryptase genotyping has an expanding role in the screening, diagnosis, and management of patients with systemic mastocytosis (SM). Reference ranges for basal serum tryptase (BST) based on increased ...

DelveInsight's, “Systemic Mastocytosis Pipeline Insight, 2025,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Systemic Mastocytosis pipeline landscape.

I want to see what is behind my eyes. Those brown eyes no longer show the thrill of living an exciting life. Even though I was battling indolent systemic mastocytosis (SM), I was constantly on the go ...

Novel diagnosis and treatment approaches for mastocytosis in the skin (MIS), a condition that may indicate underlying systemic mastocytosis (SM), have been outlined in a new clinical review published ...

Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 ...

Mastocytosis is a group of diseases characterized by proliferation and accumulation of mast cells in various organs such as the skin, bone marrow, liver, spleen, and lymph nodes. 1 Cutaneous ...

Histological examination was consistent with mastocytosis. Initial serum level tryptase was 111 ng/ml; however, instrumental investigations did not reveal any visceral involvement and C-kit molecular ...

PARIS (Reuters) -French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation, a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, ...